Chip Technology Identifies Potential Combo Therapy for ALS in Study

Chip Technology Identifies Potential Combo Therapy for ALS in Study

Chip technology — much like an organ-on-a-chip that can simulate the workings of tissue or organs  — was used to recreate amyotrophic lateral sclerosis (ALS), allowing researchers to identify two treatments for blood cancers — rapamycin plus bosutinib — as a possible ALS combination therapy. The study, “Microphysiological 3D model…

Always Learn Something!

If you are living with ALS, here’s a question for you: When was the last time you spent the time to learn something? It can’t include watching a TV newscast or scanning the news feed on your mobile device. I mean quality time spent with books or…

Health Canada Authorizes Radicava for Treatment of ALS

Canadian authorities have approved the sale of Radicava (edaravone) to treat patients with amyotrophic lateral sclerosis (ALS). The therapy will be marketed by Mitsubishi Tanabe Pharma Canada (MTP-CA), a unit of Mitsubishi Tanabe Pharma America. MTP-CA was established earlier this year to distribute Radicava and other medicines for difficult-to-treat…

Augmentative and Alternative Communication is Key to Treat Speech Disorders in ALS Patients, Study Shows

Personalized assessment and intervention with a specific communication strategy are key to improving communication in patients with amyotrophic lateral sclerosis (ALS). Dysarthria, the term for a group of speech disorders, affects 95% of patients with ALS. Augmentative and alternative communication (AAC), which includes aided and unaided approaches such as communication books…

BioElectron’s EPI-589 Shows Positive Results in ALS Patients in Phase 2a Trial

Investigational compound EPI-589 was found to be safe and well-tolerated, improved biomarkers of neuroinflammation, and showed signs of slowing disease progression in amyotrophic lateral sclerosis (ALS) patients, according to a completed Phase 2a clinical trial. BioElectron Technology Corporation’s EPI-589, or (R)-troloxamide quinone, is a 250 mg immediate-release, film-coated…